Portola Pharmaceuticals (NASDAQ:PTLA) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.

Other research analysts also recently issued reports about the company. ValuEngine raised Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 4th. Citigroup lifted their price target on Portola Pharmaceuticals to $64.00 and gave the stock a “buy” rating in a research report on Monday, May 7th. Oppenheimer set a $80.00 price target on Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, May 6th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $46.00 price target (up from $31.00) on shares of Portola Pharmaceuticals in a research report on Monday, May 7th. Finally, Zacks Investment Research downgraded Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 19th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $52.17.

Shares of PTLA stock opened at $28.51 on Wednesday. The company has a current ratio of 6.69, a quick ratio of 6.59 and a debt-to-equity ratio of 0.91. Portola Pharmaceuticals has a twelve month low of $24.63 and a twelve month high of $64.56. The company has a market capitalization of $1.86 billion, a P/E ratio of -5.93 and a beta of 1.76.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.49) by ($0.12). Portola Pharmaceuticals had a negative net margin of 1,503.29% and a negative return on equity of 111.64%. The company had revenue of $4.01 million during the quarter, compared to the consensus estimate of $6.35 million. During the same period in the previous year, the business posted ($1.22) earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. research analysts forecast that Portola Pharmaceuticals will post -5.77 EPS for the current year.

In other news, CEO William Lis sold 5,113 shares of Portola Pharmaceuticals stock in a transaction that occurred on Wednesday, June 6th. The stock was sold at an average price of $45.21, for a total transaction of $231,158.73. Following the sale, the chief executive officer now owns 222,035 shares of the company’s stock, valued at approximately $10,038,202.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Bird acquired 137,563 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The shares were purchased at an average cost of $25.17 per share, for a total transaction of $3,462,460.71. The disclosure for this purchase can be found here. Insiders own 4.60% of the company’s stock.

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Portola Pharmaceuticals during the 1st quarter worth approximately $128,000. SeaCrest Wealth Management LLC acquired a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $191,000. BB&T Securities LLC acquired a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $201,000. Silvant Capital Management LLC acquired a new stake in shares of Portola Pharmaceuticals during the 1st quarter worth approximately $186,000. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of Portola Pharmaceuticals during the 2nd quarter worth approximately $230,000. 94.26% of the stock is currently owned by institutional investors.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.

Featured Story: Are analyst ratings accurate?

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.